ArticleInternational dental journal2025
A Pyrroloquinazoline Analogue Regulated Streptococcus mutans and Streptococcus sanguinis Dual-Species Biofilms.
Article in International dental journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Polysaccharide-stabilized biogenic CuO/SeORSC advances · 2026Article
- An Oxygen-Releasing Mouthwash Reduces Porphyromonas gingivalis Biofilm and Suppresses fimA and hagA Expression.International dental journal · 2026Article
- Automation of Polysaccharide Quantification: A Rapid High-Throughput Assay Enabled by Liquid Handling Technology.Biotech (Basel (Switzerland)) · 2026Article
- Antibacterial effect of a dental adhesive containing SCH-79797 onFrontiers in cellular and infection microbiology · 2026Article
- Naringin as a non-antibiotic agent for multi-species oral biofilm control:Frontiers in microbiology · 2025Article
- A brief review of membrane vesicles fromFrontiers in microbiology · 2025Review
- Zoliflodacin inhibitsFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSelective inhibition of cariogenic bacteria is regarded as a potential strategy against caries. To assess the potential of SCH-79797, one novel promising antibiotic, in microbial equilibrium using a dual-species biofilms model of Streptococcus mutans (S. mutans) and Streptococcus sanguinis (S. sanguinis).
methodsBiofilm biomass and metabolic activity were disclosed using the MTT and crystal violet staining methods. Besides, bacteria/exopolysaccharide staining and anthrone method were applied to measure extracellular polysaccharides (EPS) synthesis, while lactic acid measurement was used to assess acid production. Then, quantitative real-time PCR (qRT-PCR) was employed to investigate gene variation related to polysaccharide production and interspecies competition within dual-species biofilm. The dual-species biofilm configuration was mirrored by fluorescence in situ hybridization (FISH). Growth of the planktonic bacteria was reflected by growth curve. Lastly, bacterial cell membranes were visualized by transmission electron microscope (TEM).
resultsWithin dual-species biofilm, SCH-79797 not only abated biomass, metabolic activity, EPS as well as acid generation but also decreased the proportion of opportunistic cariogenic S. mutans. Besides, polysaccharides production and competition-related genes (gtfP, spxB) in S. sanguinis were up-regulated, whereas these associated genes (gtfB, gtfC, gtfD, and nlmD) in S. mutans were down-regulated inside dual-species biofilm which displayed decreased S. mutans ratio. Additionally, SCH-79797 had a selective inhibitory effect on S. mutans rather than S. sanguinis, including biofilm's biomass, metabolic activity, acid and polysaccharides generation, bacterial growth, and cell membrane integrity.
conclusionsSCH-79797 showed regulatory effects on controlling dual-species biofilm ecologically, indicating its potential to be a latent anticaries agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.